Morgan Stanley Pathway Small-Mid Cap Equity ETF
MSSM - ETF AI Analysis
Top Page
Morgan Stanley Pathway Small-Mid Cap Equity ETF (MSSM)
MSSM, the Morgan Stanley Pathway Small-Mid Cap Equity ETF, has an overall rating that suggests a generally solid but mixed-quality portfolio of smaller companies. Strong contributors like Dynatrace and Texas Capital Bancshares help the fund’s rating with robust revenue growth, improving profitability, and supportive technical trends, while weaker names such as Ascendis Pharma and Moderna, which face ongoing losses and financial challenges, weigh on the overall picture. The main risk factor is the fund’s exposure to several highly leveraged and overbought stocks, which could make performance more volatile if market conditions turn negative.
MSSM vs. SPDR S&P 500 ETF (SPY)
- AUM
- 705.72M
- Region
- North America
- Expense Ratio
- 0.62%
- Beta
- 0.95
- Issuer
- Morgan Stanley
- Inception Date
- Dec 09, 2024
- Dividend Yield
- 2.70%
- Asset Class
- Equity
- Index Tracked
- No Underlying Index
MSSM Summary
The Morgan Stanley Pathway Small-Mid Cap Equity ETF (MSSM) invests in smaller and mid-sized U.S. companies, rather than tracking a specific index. It focuses on the “extended market,” aiming to find growing businesses that may be overlooked compared with big, well-known stocks. The fund holds a mix of sectors like technology, health care, and industrials, with names such as Moderna and Dynatrace among its top positions. Investors might consider MSSM for growth potential and added diversification beyond large caps. However, small and mid-cap stocks can be more volatile, so the ETF’s price can move up and down more sharply than the overall market.
How much will it cost me?
This ETF has an expense ratio of 0.62%, which means you’ll pay about $6.20 per year for every $1,000 invested. That’s higher than the average ETF because it’s actively managed and focuses on a specialized group of small- and mid-cap stocks, which typically costs more to run than broad, passive index funds.
What would affect this ETF?
MSSM could benefit if the U.S. economy stays healthy and innovation-driven, since its focus on smaller technology, industrial, and health care companies means it may gain from business growth and new products at firms like Dynatrace and Moderna. On the downside, small- and mid-cap stocks can be hit harder by economic slowdowns, rising interest rates, or tighter credit, and sector-specific issues in areas like health care regulation or tech spending could weigh on the fund’s performance.
MSSM Top 10 Holdings
MSSM leans into U.S. small and mid-cap growth stories, with tech and health care doing much of the heavy lifting. Dynatrace and Haemonetics have been rising steadily, acting like quiet engines for the fund, while ViaSat’s strong momentum adds extra thrust despite some profitability hiccups. On the flip side, Ascendis Pharma has been more mixed, occasionally losing steam, and Veeco has recently lagged, trimming some of the upside. Financial names like Texas Capital Bancshares provide a steady backbone, giving this domestically focused ETF a diversified but growth-tilted profile.
| Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
 ASND | Ascendis Pharma | 0.78% | $5.51M | $16.01B | 28.89% | 46Neutral |
 KBR | KBR | 0.66% | $4.66M | $4.91B | -14.47% | 73Outperform |
 MRNA | Moderna | 0.63% | $4.43M | $101.49B | 841.65% | 59Neutral |
 HAE | Haemonetics | 0.60% | $4.21M | $5.57B | 68.05% | 70Outperform |
 LTH | Life Time Group Holdings | 0.57% | $3.99M | $10.65B | 84.90% | 71Outperform |
 VSAT | ViaSat | 0.71% | $5.02M | $10.42B | 97.10% | 56Neutral |
 DT | Dynatrace | 0.57% | $4.00M | $12.48B | -5.51% | 77Outperform |
 EAT | Brinker International | 0.49% | $3.44M | $8.11B | 89.71% | 70Neutral |
 TCBI | Texas Capital Bancshares | ― | ― | ― | ― | 79Outperform |
 BTSG | BrightSpring Health Services, Inc. | 0.58% | $4.06M | $14.42B | 114.16% | 67Neutral |
MSSM Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For MSSM, the sentiment is Positive. The current price of 59.08 is above the 20-day moving average (MA) of 57.73, above the 50-day MA of 57.82, and above the 200-day MA of 57.37, indicating a bullish trend. The MACD of 0.24 indicates Negative momentum. The RSI at 57.24 is Neutral, neither overbought nor oversold. The STOCH value of 86.96 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for MSSM.
MSSM Peer Comparison
Comparison Results
| Name | Price | Price Target | AUM | Expense Ratio | Overall Rating |
|---|---|---|---|---|---|
| MSSM | $59.08 | $61.00(3.25% Upside) | $705.72M | 0.62% | 64Neutral |
 RSMC | $28.23 | $34.56(22.41% Upside) | $742.45M | 0.75% | 68Neutral |
 GRNJ | $25.85 | $38.59(49.27% Upside) | $408.20M | 0.75% | 69Neutral |
 ASCE | $33.18 | $42.72(28.76% Upside) | $398.58M | 0.38% | 71Outperform |
 SMIZ | $40.91 | $48.80(19.29% Upside) | $271.88M | 0.55% | 68Neutral |
 RNIN | $38.62 | $45.13(16.84% Upside) | $212.80M | 0.68% | 69Neutral |
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| MSSM | Morgan Stanley Pathway Small-Mid Cap Equity ETF | 59.08 | 10.35 | 21.23% | |
| RSMC | Rockefeller U.S. Small-Mid Cap ETF | 28.23 | 2.92 | 11.55% | |
| GRNJ | Fundstrat Granny Shots US Small- & Mid-Cap ETF | 25.85 | 1.55 | 6.38% | |
| ASCE | Allspring SMID Core ETF | 33.18 | 7.67 | 30.09% | |
| SMIZ | Zacks Small/Mid Cap ETF | 40.91 | 4.57 | 12.58% | |
| RNIN | Bushido Capital US SMID Cap Equity ETF | 38.62 | 11.91 | 44.57% |
This AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.